Retraction notice to “Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer” [Heliyon 9 (2023) e15782]

Ítems similars

• A Novel Highly Sensitive Chemiluminescence Enzyme Immunoassay with Signal Enhancement Using Horseradish Peroxidase-Luminol-Hydrogen Peroxide Reaction for the Quantitation of Monoclonal Antibodies Used for Cancer Immunotherapy
  per: Ibrahim A. Darwish, et al.
  Publicat: (2023-04-01)
• A Multi-Center Assessment of Thyroid Function Test Precision in Chemiluminescence Immunoassay (CLIA) Systems
  per: Mahendra Prasad Bhatt, et al.
  Publicat: (2018-12-01)
• Retraction notice to “Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer” [Heliyon 9 (2023) e15782]
  per: Ibrahim A. Darwish, et al.
  Publicat: (2023-11-01)
• Analytical and clinical performance evaluation of the Wantai chemiluminescence microparticle immunoassay on the Wan200 + analyzer for diagnosing HIV
  per: Jianfeng Chen, et al.
  Publicat: (2025-05-01)
• Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
  per: Jiahao Zhang, et al.
  Publicat: (2025-01-01)